Semaglutide news today: the UK developments that actually matter

The oral semaglutide approval: what the clinical evidence showed

When the MHRA cleared Wegovy tablets in June 2026, it was drawing on the OASIS 4 phase-3 trial: 307 adults with obesity or overweight plus at least one weight-related condition, followed for 64 weeks, compared against placebo alongside lifestyle changes. Average weight loss across everyone who took the tablet, regardless of how consistently they took it, was around 13.6% — against roughly 2.4% for placebo. Among participants who stayed fully adherent throughout the trial, the figure rose to approximately 16.6%.

That adherence gap is worth dwelling on for a moment. A widespread assumption is that tablets are always simpler than injections, so compliance will be automatic. In practice, the Wegovy tablet has specific requirements: taken first thing in the morning on an empty stomach, with no more than a small amount of plain water, waiting at least 30 minutes before food, coffee or other medicines. Miss that window and the semaglutide absorption enhancer (SNAC) cannot do its job properly. The evidence tells a clear story about what careful adherence can deliver; it also tells you that the tablet asks something of the person taking it.

Dosing starts at 1.5mg and escalates through 4mg and 9mg to the 25mg maintenance dose, with a minimum of one month at each level. If you want to read more about what is new with semaglutide, including how the oral formulation fits alongside existing options, that page brings together the latest developments in one place. You can find the full clinical detail in the NHS semaglutide medicines page, which has been updated to reflect the new formulation.

The 7.2mg injection pen: how the evidence behind a higher dose developed

Semaglutide Wegovy news from earlier in 2026 centres on the higher-dose injection, which has two distinct moments. The MHRA first approved a 7.2mg maintenance dose in January 2026, initially supplied as three 2.4mg pens used in a single week. Then, on 14 April 2026, the regulator approved a dedicated single-dose 7.2mg pen, one pre-set weekly injection with an auto-dosing mechanism, a built-in covered needle that locks after use.

Trial data reported average weight loss of around 20.7% over 72 weeks at the 7.2mg dose. That figure matters in context: the STEP 1 trial published in the New England Journal of Medicine had shown roughly 15% average reduction with the 2.4mg maintenance dose at 68 weeks. The higher dose narrows the gap between semaglutide and tirzepatide results, which generated significant clinical interest when the data emerged.

One important licensing boundary: the 7.2mg pen is approved for adults with BMI 30 or above only. It does not cover the BMI 27–29.9 range with a weight-related condition that the lower-dose injection can address, and it is not authorised for the cardiovascular indication. Those distinctions are exactly the kind of detail a prescriber works through, not a checklist the patient is expected to apply to themselves. For a broader picture of what semaglutide is and how it works, the semaglutide overview covers the mechanism in full.

The MASH indication: a third use for semaglutide that most people haven't heard of

On 3 July 2026 the MHRA granted a conditional approval for Wegovy (semaglutide) in metabolic dysfunction-associated steatohepatitis (MASH) a progressive form of fatty liver disease characterised by inflammation and scarring. This is a significant development in hepatology, where treatment options for moderate-to-advanced fibrosis have historically been limited.

This approval is worth noting clearly in the context of the latest semaglutide news, which covers this and other recent regulatory changes across the full range of approved uses, even though it is outside the weight-management indication that most readers are investigating. According to the official MHRA announcement on GOV.UK (3 July 2026), the approval is conditional, meaning further evidence is required as part of the post-authorisation commitment. It is a specialist hepatology decision, not something a general weight-management prescriber would initiate.

At nume, prescribing is for weight management. If you are living with a liver condition and wondering whether semaglutide is relevant to you, that conversation belongs with your hepatology team first. More on the full current picture of semaglutide approvals can be found on the Wegovy news page.

What none of this changes about how you access semaglutide

New approvals, new doses, new formulations, none of it changes the legal framework. Semaglutide remains a prescription-only medicine under the Human Medicines Regulations 2012. No amount of clinical enthusiasm about a trial result converts that. You need a prescriber who has assessed your health history, your current medicines, and whether the benefit-to-risk balance makes sense for you specifically.

The NICE recommendation for Wegovy (TA875) requires treatment within a specialist weight management service for NHS access and sets a maximum treatment duration of two years. If you want to understand what Wegovy is, how it works and who it is suitable for, that page sets out the full picture, including the eligibility criteria and how private prescribing sits alongside NHS access. If you want to understand whether you might be eligible, the weight-loss treatment overview sets out the licensed eligibility criteria honestly, and the frequently asked questions covers the questions our prescribers hear most often.

For anyone actively considering semaglutide as a weight-management option, the most useful next step is a free consultation with a prescriber who can look at your situation rather than a generalised eligibility checklist. You can also keep up with the latest news on Wegovy, including any further updates to dosing, availability and approvals as they are announced. Start your free consultation and a GPhC-registered Independent Prescriber will review it the same day.